New Migraine Drugs Cut Pain Days With Fewer Side Effects

A comprehensive review published in the journal *Annals of Internal Medicine* has found that a newer class of migraine medications—those targeting the CGRP protein—are among the most effective options currently available. The analysis, which examined 43 clinical trials involving adults with chronic migraine (defined as 15 or more headache days per month), shows these drugs reduce the number of headache days by an average of two per month and are generally well tolerated by patients.

Key medications in this class include eptinezumab (sold as Vyepti) and atogepant (sold as Qulipta). The CGRP protein plays a central role in migraine attacks, with levels rising in the brain and nervous system during episodes, triggering pain and inflammation. These newer therapies are specifically designed to disrupt that process.

Treatment Options and Tolerability

The CGRP-targeting drugs come in multiple forms, including injections, intravenous solutions, tablets, and nasal sprays. Evidence indicates they cause fewer side effects compared to conventional migraine treatments.

In contrast, some older therapies showed less clear results. Botox (botulinum toxin) may offer limited benefit, but the review noted a lower degree of certainty about its effectiveness and a higher likelihood of side effects that could lead some patients to stop treatment. For drugs such as topiramate, valproate, and propranolol, the evidence of efficacy was described as limited and less reliable.

Need for Further Research

Despite the promising findings, the researchers emphasize the need for more independent studies, particularly to assess the long-term safety of these drugs and patient adherence to them. The study was led by researcher Malahat Khalili from McMaster University in Canada.

The experts conclude that choosing the most appropriate treatment depends not only on efficacy but also on the patient’s needs, preferences, and cost, stressing the importance of consulting a healthcare provider for the right decision.